Results 181 to 190 of about 368,793 (264)

POEMS Syndrome: 2026 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, EarlyView.
ABSTRACT Disease Overview POEMS syndrome is a life‐threatening syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease.
Angela Dispenzieri
wiley   +1 more source

Low-dose EGFR inhibition unlocks ferroptosis susceptibility to sensitize chemotherapy in EGFR-high triple-negative breast cancer. [PDF]

J Biol Chem
Li X, Liu L, Luo L, Deng M, Jiang Y, Ren W, Qian H.   +6 more
europepmc   +1 more source

Proteome‐Wide Target Identification Using Reactive Metallo‐Scaffolds (r‐mS): A Platform for Metallodrug Discovery

Angewandte Chemie, EarlyView.
Re‐envisioning the Ligandable Proteome: Reactive Metallo‐Scaffolds (r‐mS) combine non‐covalent protein engagement by a metallo‐scaffold with covalent cysteine capture through a tethered chloroacetamide warhead. Chemoproteomic profiling reveals unique enzyme engagement including ligases, kinases and methyltransferases, highlighting opportunities for ...
Jessica E. Waters, Harry Wilders, George S. Biggs, Mika Kintzel, Emma E. Cawood, Jonathan Bailey, Sarah Maslen, Yew Mun Yip, Mason Wakley, Ioannis G. Riziotis, Thomas W. Rees, Joanna Redmond, J. Mark Skehel, David House, Jacob Bush, Jeannine Hess   +15 more
wiley   +2 more sources

Atherogenic index of plasma predicts progression of diabetic kidney disease. [PDF]

Front Med (Lausanne)
Shih HM, Liu SC, Chien KL, Fan HY, Tsai MC, Chuang SM.   +5 more
europepmc   +1 more source

Nuclear factor of activated T cells as a driver of tumor progression and a target for precision therapy

Animal Models and Experimental Medicine, EarlyView.
Overview illustration of dysregulated NFAT activation coordinating upstream signaling, post‐translational regulation and cancer promoting pathways to induce abnormal gene expression that drives tumor development, progression and immune escape. Abstract The Nuclear Factor of Activated T Cells (NFAT) family comprises closely related transcription factors.
Hira Khan, Khushbakhat Alia, Yusra Al Dhaheri, Muhammad Naseem, Rabah Iratni, Edgar Serfling, Khalid Muhammad   +6 more
wiley   +1 more source

A network pharmacology and molecular docking approach to investigate the anticancer mechanism of baicalin against melanoma through induction of apoptosis via EGFR-mediated PI3K/AKT pathway. [PDF]

Transl Cancer Res
He Z, Huang A, Lv J, Zhou J, Lou W, Xu B, Wu X.   +6 more
europepmc   +1 more source

Rewriting Tumor Immunity With Bacterial Membrane Vesicles: A Versatile and Potent Therapeutic Strategy

Advanced NanoBiomed Research, EarlyView.
Bacterial membrane vesicles (BMVs) emerge as promising platforms for cancer immunotherapy owing to their intrinsic adjuvant properties and tunable cargo delivery capabilities. Their ability to modulate the tumor microenvironment, enhance antitumor immune responses, and support personalized therapeutic strategies highlights their growing potential as ...
Md Sifat Rahi, Md Mijanur Rahman, Asma Talukder, Urooj Yousaf Virk, Jennifer C. Wilson, Nigel McMillan, Ming Q. Wei   +6 more
wiley   +1 more source

MiR-23c Regulates the Resistance to Gefitinib in EGFR Mutant Non-Small-Cell Lung Cancer Cells. [PDF]

Cells
Ignoto B, Parisi IA, Roma C, Camerlingo R, Dotolo S, Tufano S, Maiello MR, Normanno N, Morabito A, De Luca A, Frezzetti D.   +10 more
europepmc   +1 more source

Comparison of Receptor‐Mediated Endocytosis and Its Application to Enhance DNA Transfection by TFAMoplex

Advanced NanoBiomed Research, EarlyView.
We developed an assay to distinguish cellular binding from internalization. Compatible with microscopy and high‐throughput screening, the method identifies ligand‐mediated uptake. Applying top candidates to a protein‐based DNA carrier enhanced transfection efficiency, providing a rational strategy to improve non‐viral gene delivery systems.
David Scherer, Steffen Honrath, Jonas Kurmann, Alexander Klipp, Finn Brigger, Jean‐Christophe Leroux   +5 more
wiley   +1 more source

Dynamic therapeutic response to osimertinib and immunotherapy in an EGFR L747S and L858R co-mutant NSCLC. [PDF]

Oncologist
Tan Y, Wang T, Yu J, Ouyang W.
europepmc   +1 more source